Your browser doesn't support javascript.
loading
Use of IV immunoglobulin to treat steroid resistant, immune checkpoint inhibitor-induced pure red cell aplasia: A case report.
Sherratt-Mayhew, Sam; Nicolson, Phillip L R.
Afiliação
  • Sherratt-Mayhew S; Institute of Cardiovascular Sciences University of Birmingham Birmingham UK.
  • Nicolson PLR; Institute of Cardiovascular Sciences University of Birmingham Birmingham UK.
EJHaem ; 5(4): 825-828, 2024 Aug.
Article em En | MEDLINE | ID: mdl-39157612
ABSTRACT
Pure red cell aplasia (PRCA) is characterised by normocytic normochromic anaemia, reticulocytopenia and reduced erythroid precursors in bone marrow. PRCA as an immune-related adverse event secondary to immune checkpoint inhibitor (ICI) therapy is rare. Steroids are usually used first line to treat ICI-induced PRCA. Here, we report a case of ICI-induced PRCA with no response to steroids but where intravenous (IV) immunoglobulin was successfully used second line. ICI therapy was reinitiated following PRCA resolution. PRCA recurrence did not occur.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article